In 2012, Rossi et al. reported, in a prospective study on 1150 patients operated on for breast cancer (88% hormone receptor-positive tumors), worse RFS for tumors with HER2 2+/FISH-negative status (n = 116 patients, among whom 29 had TNBC) compared with HER2 0/1+ tumors. The gene discussed is ERBB2; the disease is breast cancer.